All Stories

  1. Dual prodrugs of N4-hydroxycytidine with ProTide and ester modifications as anti-SARS-CoV-2 agents
  2. Design and anti-rhinovirus activity of novel derivatives based on the pleconaril core
  3. Antiviral sugar baits to reduce arbovirus transmission: a proof-of-concept study
  4. Accelerating the clinical development of treatments for dengue: WHO dengue therapeutics landscape analysis and target product profiles
  5. Oropouche virus causes severe congenital disease in embryonic mice
  6. The 5′-Isobutyryl Ester Prodrug of 4′-Thiouridine Inhibits SARS-CoV-2 Replication in Culture and in a Syrian Hamster Infection Model
  7. Discovery of orally bioavailable N-acylated remdesivir derivatives with potent broad-spectrum antiviral activity
  8. Cross-protection against Bundibugyo by Ebola and Sudan vaccines
  9. Estimating the in vivo prophylactic effect of mosnodenvir, a novel dengue antiviral, on DENV-2 infection
  10. Rat hepatitis E virus infection has multiphasic viral replication kinetics in vivo
  11. A robust cell-based infection model for Rhinovirus C research and antiviral drug discovery
  12. An orthoflavivirus inhibitor targeting multifunctional NS2A protein, a previously unidentified target
  13. 2‐Phenylquinolines Exhibit Anti‐Severe Acute Respiratory Syndrome Coronavirus‐2 Activity Through the Nonstructural Protein 13 Helicase Inhibition
  14. Thymidine kinase-expressing yellow fever 17D reporter virus facilitates prodrug activation and bioorthogonal labelling of infected cells
  15. CD4+ T cell-mediated immunity protects from VSV-SUD lethal challenge in a mouse model of Sudan virus infection
  16. A clinical SARS-CoV-2 Mpro inhibitor blocks replication of multiple enteroviruses and confers oral in vivo protection in animal models
  17. A High-Throughput Antiviral Assay Based on a Sindbis Virus-GFP for the Discovery of Inhibitors of Alphavirus Replication
  18. COVID-19-related inflammation of the placenta impedes fetal development in pregnant hamsters
  19. New 1,2,3-triazole-α-aminophosphonate acyclic nucleosides scaffold: Design, synthesis, docking studies and biological evaluation as potential S. aureus agents
  20. Thiazolyl 4-carboxylate ketone as a new warhead for a highly potent SARS-CoV-2 main protease inhibitor
  21. Human Myelin Spheres for in Vitro Oligodendrocyte Maturation, Myelination and Neurological Disease Modeling
  22. Proliferative Cell Targeting and Epithelial Cell Turnover Fuels Hepatitis E Virus Replication in Human Intestinal Enteroids
  23. 2-amido-3-aryl-4-methyl-thiazole derivatives as broad-spectrum anti-rhinoviral agents
  24. Phosphoinositide kinase PIKfyve inhibitor apilimod blocks hepatitis E virus infection
  25. Design, Synthesis, and Evaluation of Anti-Orthoflavivirus Anchimerically HINT1‑Activatable (AHA) ProTides
  26. Immunological and transcriptomic profile of chimeric live-attenuated Zika vaccine linked to protection in non-human primates
  27. Antiviral activities of phenylalanine derivatives carrying carboxylic acid bioisosteres against chikungunya and parainfluenza virus type 3
  28. Oropouche virus causes severe congenital disease in embryonic mice
  29. 1′-Cyanocytidine-5′-isobutyryl is a potent SARS-CoV-2 inhibitor in culture and infected Syrian hamsters
  30. Synthesis and antiviral activity of thiazolyl hydrazones against dengue virus
  31. Identification and Exploration of a Series of SARS-Cov-2 MPro Cyano-Based Inhibitors Revealing Ortho-Substitution Effects within the P3 Biphenyl Group
  32. Correction to “Discovery of Novel Arylethynyltriazole Ribonucleosides with Selective and Effective Antiviral and Antiproliferative Activity”
  33. Meeting report: 38th international conference on antiviral research in Las Vegas, United States of America, March 17–21, 2025
  34. High-throughput split-GFP antiviral screening assay against fusogenic paramyxoviruses
  35. The Indispensable Value of Small-Molecule Antivirals in Epidemic and Pandemic Preparedness
  36. New spirooxindole-benzothiazole hybrids incorporating a trifluoromethyl moiety as antiviral agents: Design, synthesis, crystal structure analysis, and in silico studies
  37. The multifaceted role of the viral 2A protease in enterovirus replication and antagonism of host antiviral responses
  38. PIP4K2C inhibition reverses autophagic flux impairment induced by SARS-CoV-2
  39. Combinations of approved oral nucleoside analogues confer potent suppression of alphaviruses in vitro and in vivo
  40. Discovery and Preclinical Profile of ALG-097558, a Pan-Coronavirus 3CLpro Inhibitor
  41. Discovery of orally bioavailable Zika and West Nile Virus antiviral compounds targeting the NS2B-NS3 protease
  42. Open-science discovery of DNDI-6510, a compound that addresses genotoxic and metabolic liabilities of the COVID Moonshot SARS-CoV-2 Mpro lead inhibitor
  43. Discovery of Small Molecules Targeting Norovirus 3CL Protease by Multi-Stage Virtual Screening
  44. Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base
  45. Human Myelin Spheres for In Vitro Oligodendrocyte Maturation, Myelination and Neurological Disease Modeling
  46. Functional Humoral Response During Intranasal Convalescent Plasma Prophylaxis for Severe Acute Respiratory Syndrome Coronavirus 2
  47. 6-Chlorocoumarin Conjugates with Nucleobases and Nucleosides as Potent Anti-Hepatitis C Virus Agents
  48. A coronavirus assembly inhibitor that targets the viral membrane protein
  49. A small-molecule SARS-CoV-2 inhibitor targeting the membrane protein
  50. The Combination of GS-441524 (Remdesivir) and Ribavirin Results in a Potent Antiviral Effect Against Human Parainfluenza Virus 3 Infection in Human Airway Epithelial Cell Cultures and in a Mouse Infection Model
  51. Combinations of approved oral nucleoside analogues confer potent suppression of alphaviruses in vitro and in vivo
  52. Structure-Based Optimization of Pyridone α-Ketoamides as Inhibitors of the SARS-CoV-2 Main Protease
  53. Optimization of SARS-CoV-2 Mpro Inhibitors by a Structure-Based Multilevel Virtual Screening Method
  54. The Dissemination of Rift Valley Fever Virus to the Eye and Sensory Neurons of Zebrafish Larvae Is Stat1-Dependent
  55. The combination of GS-441524 (remdesivir) and ribavirin results in a potent antiviral effect against human parainfluenza virus 3 infection in human airway epithelial cell cultures and in a mouse infection model
  56. Design, synthesis and evaluation of arylpurine-based sinefungin mimetics as zika virus methyltransferase inhibitors
  57. Epidemic Zika virus strains from the Asian lineage induce an attenuated fetal brain pathogenicity
  58. Antigenic Imprinting Dominates Humoral Responses to New Variants of SARS-CoV-2 in a Hamster Model of COVID-19
  59. Human norovirus disturbs intestinal motility and transit time through its capsid proteins
  60. Transcriptional profiling of zebrafish intestines identifies macrophages as host cells for human norovirus infection
  61. Protecting Group Control of Hydroxyketone-Hemiketal Tautomeric Equilibrium Enables the Stereoselective Synthesis of a 1′-Azido C-Nucleoside
  62. The effects of Remdesivir’s functional groups on its antiviral potency and resistance against the SARS-CoV-2 polymerase
  63. The triple combination of Remdesivir (GS-441524), Molnupiravir and Ribavirin is highly efficient in inhibiting coronavirus replication in human nasal airway epithelial cell cultures and in a hamster infection model
  64. A Pangenotypic Hepatitis E Virus Replication Inhibitor With High Potency in a Rat Infection Model
  65. Antigenic imprinting dominates humoral responses to new variants of SARS-CoV-2 in a hamster model of COVID-19
  66. Thymidine kinase-expressing yellow fever 17D reporter virus facilitates prodrug activation and bioorthogonal labelling of infected cells
  67. The tyrosine kinase Yes1 is a druggable host factor of HEV
  68. Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2, and Exploring the Effect of Raltegravir on the Activity of SARS-CoV-2
  69. A robust mouse model of HPIV-3 infection and efficacy of GS-441524 against virus-induced lung pathology
  70. A Hepatitis E Virus Infection Model in the Mongolian Gerbil: Ready for Antiviral and Vaccine Studies
  71. Pan-serotype dengue virus inhibitor JNJ-A07 targets NS4A-2K-NS4B interaction with NS2B/NS3 and blocks replication organelle formation
  72. New Schiff bases and their vanadium complexes: Synthesis, characterization, and biological assessment for antibacterial and antiviral action
  73. Standing the test of COVID-19: charting the new frontiers of medicine
  74. The triple combination of Remdesivir (GS-441524), Molnupiravir and Ribavirin is highly efficient in inhibiting coronavirus replication in human nasal airway epithelial cell cultures and in a hamster infection model
  75. A robust mouse model of human parainfluenza 3 virus infection and efficacy of GS-441524, the parent nucleoside of remdesivir, against lung pathology
  76. Challenges in combating arboviral infections
  77. Mechanism of action of phthalazinone derivatives against rabies virus
  78. Hepatitis E virus replication is facilitated by epithelial cell turnover and targets enteroendocrine cells in human intestinal organoids
  79. Design, synthesis, and molecular modeling studies of novel 2-quinolone-1,2,3-triazole-α-aminophosphonates hybrids as dual antiviral and antibacterial agents
  80. Beware of drug resistance: Let’s not lose tecovirimat against mpox
  81. Lower respiratory tract single-cell RNA sequencing and neutrophil extracellular trap profiling of COVID-19-associated pulmonary aspergillosis: a single centre, retrospective, observational study
  82. Molnupiravir inhibits human norovirus and rotavirus replication in 3D human intestinal enteroids
  83. Discovery of JNJ-1802, a First-in-Class Pan-Serotype Dengue Virus NS4B Inhibitor
  84. Integrating artificial intelligence-based epitope prediction in a SARS-CoV-2 antibody discovery pipeline: caution is warranted
  85. Comparing the Infectivity of Recent SARS-CoV-2 Omicron Sub-Variants in Syrian Hamsters
  86. Multiplexed multicolor antiviral assay amenable for high-throughput research
  87. Genetic consequences of effective and suboptimal dosing with mutagenic drugs in a hamster model of SARS-CoV-2 infection
  88. Design, synthesis, and lead optimization of piperazinyl-pyrimidine analogues as potent small molecules targeting the viral capping machinery of Chikungunya virus
  89. Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors
  90. A new alkaloid from Pancratium maritimum - Structure elucidation using computer-assisted structure elucidation (CASE) and evaluation of cytotoxicity and anti-SARS-CoV-2 activity
  91. Lack of antiviral activity of probenecid in vitro and in Syrian golden hamsters
  92. A Robust Phenotypic High-Throughput Antiviral Assay for the Discovery of Rabies Virus Inhibitors
  93. Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors
  94. Anti-SARS-CoV-2 activity of cyanopeptolins produced by Nostoc edaphicum CCNP1411
  95. Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters
  96. Comprehensive study of alkaloids from Scadoxus multiflorus by HPLC-PDA-SPE-NMR and evaluation of their anti-SARS-CoV-2 activity
  97. Anticancer pan-ErbB inhibitors reduce inflammation and tissue injury and exert broad-spectrum antiviral effects
  98. Establishment of a robust rat hepatitis E virus fecal-oral infection model and validation for antiviral studies
  99. YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge
  100. Discovery of Acyl-Indole Derivatives as Pan-Serotype Dengue Virus NS4B Inhibitors
  101. Author Correction: Reverse engineering synthetic antiviral amyloids
  102. Towards antivirals against hepatitis E: In the steps of hepatitis C
  103. Antiviral strategies for epidemic and pandemic preparedness
  104. Intranasal administration of convalescent plasma protects against SARS-CoV-2 infection in hamsters
  105. Immunovirological and environmental screening reveals actionable risk factors for fatal COVID-19 during post-vaccination nursing home outbreaks
  106. Urtica dioica Agglutinin Prevents Rabies Virus Infection in a Muscle Explant Model
  107. Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in female Syrian hamsters and retains partial susceptibility to treatment
  108. Validation of a Reporter Cell Line for Flavivirus Inhibition Assays
  109. Anti-SARS-CoV-2 Activity and Cytotoxicity of Amaryllidaceae Alkaloids from Hymenocallis littoralis
  110. Blocking NS3–NS4B interaction inhibits dengue virus in non-human primates
  111. Identification of Z-Tyr-Ala-CHN2, a Cathepsin L Inhibitor with Broad-Spectrum Cell-Specific Activity against Coronaviruses, including SARS-CoV-2
  112. The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir
  113. Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro
  114. Insertion of an Amphipathic Linker in a Tetrapodal Tryptophan Derivative Leads to a Novel and Highly Potent Entry Inhibitor of Enterovirus A71 Clinical Isolates
  115. A pan-serotype antiviral to prevent and treat dengue: A journey from discovery to clinical development driven by public-private partnerships
  116. Development of a robust and convenient dual-reporter high-throughput screening assay for SARS-CoV-2 antiviral drug discovery
  117. Single-dose YF17D-vectored Ebola vaccine candidate protects mice against both lethal surrogate Ebola and yellow fever virus challenge
  118. Azapeptide activity-based probes for the SARS-CoV-2 main protease enable visualization of inhibition in infected cells
  119. Rational design of novel nucleoside analogues reveals potent antiviral agents for EV71
  120. Synthesis, characterization, molecular docking, and anticancer activities of new 1,3,4-oxadiazole-5-fluorocytosine hybrid derivatives
  121. Structural Investigations on Novel Non-Nucleoside Inhibitors of Human Norovirus Polymerase
  122. Identification of Polyphenol Derivatives as Novel SARS-CoV-2 and DENV Non-Nucleoside RdRp Inhibitors
  123. The Role of Histo-Blood Group Antigens and Microbiota in Human Norovirus Replication in Zebrafish Larvae
  124. Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters
  125. Anatomical barriers against SARS-CoV-2 neuroinvasion at vulnerable interfaces visualized in deceased COVID-19 patients
  126. Human Norovirus Efficiently Replicates in Differentiated 3D-Human Intestinal Enteroids
  127. Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
  128. Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters
  129. Synthesis and evaluation of 3-alkynyl-5-aryl-7-aza-indoles as broad-spectrum antiviral agents
  130. Bis(Benzofuran–1,3-N,N-heterocycle)s as Symmetric and Synthetic Drug Leads against Yellow Fever Virus
  131. SARS-CoV-2 infection causes prolonged cardiomyocyte swelling and inhibition of HIF1α translocation in an animal model COVID-19
  132. Synthesis of new 3-acetyl-1,3,4-oxadiazolines combined with pyrimidines as antileishmanial and antiviral agents
  133. Modulation of thromboinflammation in hospitalized COVID‐19 patients with aprotinin, low molecular weight heparin, and anakinra: The DAWn‐Antico study
  134. Diastereomeric Resolution Yields Highly Potent Inhibitor of SARS-CoV-2 Main Protease
  135. A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity
  136. Dysregulation of the kallikrein-kinin system in bronchoalveolar lavage fluid of patients with severe COVID-19
  137. Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models
  138. A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection
  139. The pulmonary vasculature in lethal COVID-19 and idiopathic pulmonary fibrosis at single-cell resolution
  140. Evaluation of the anti-SARS-CoV-2 properties of essential oils and aromatic extracts
  141. ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies
  142. The dissemination of Rift Valley fever virus to the eye and sensory neurons of zebrafish larvae is stat1 dependent
  143. Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19
  144. Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model
  145. Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys
  146. Cytopathic SARS-CoV-2 screening on VERO-E6 cells in a large-scale repurposing effort
  147. Computer-Aided Design and Synthesis of (Functionalized quinazoline)–(α-substituted coumarin)–arylsulfonate Conjugates against Chikungunya Virus
  148. Organotropic dendrons with high potency as HIV-1, HIV-2 and EV-A71 cell entry inhibitors
  149. A High-Throughput Yellow Fever Neutralization Assay
  150. Biodistribution and environmental safety of a live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate
  151. HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect
  152. Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
  153. Discovery of 2-Phenylquinolines with Broad-Spectrum Anti-coronavirus Activity
  154. SARS-CoV-2 Virion Infectivity and Cytokine Production in Primary Human Airway Epithelial Cells
  155. Restriction of viral replication, rather than T cell immunopathology, drives lethality in MNV CR6-infected STAT1-deficient mice
  156. Cytidine nucleoside analog is an effective antiviral drug against Trichomonasvirus
  157. Development and optimization of a high‐throughput screening assay for in vitro anti‐SARS‐CoV‐2 activity: Evaluation of 5676 Phase 1 Passed Structures
  158. Restriction of Viral Replication, Rather than T Cell Immunopathology, Drives Lethality in Murine Norovirus CR6-Infected STAT1-Deficient Mice
  159. Ivermectin Does Not Protect against SARS-CoV-2 Infection in the Syrian Hamster Model
  160. MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters
  161. The SARS-CoV-2 Alpha variant exhibits comparable fitness to the D614G strain in a Syrian hamster model
  162. Synthesis, X-ray crystallographic analysis, DFT studies and biological evaluation of triazolopyrimidines and 2-anilinopyrimidines
  163. Synthesis and antiviral activities of quinazolinamine–coumarin conjugates toward chikungunya and hepatitis C viruses
  164. Ivermectin does not protect against SARS-CoV-2 infection in the Syrian hamster model
  165. The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern
  166. Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses
  167. Synthesis, Structure–Activity Relationships, and Antiviral Profiling of 1-Heteroaryl-2-Alkoxyphenyl Analogs as Inhibitors of SARS-CoV-2 Replication
  168. Development and optimisation of a high-throughput screening assay for in vitro anti–SARS-CoV-2 activity: evaluation of 5676 phase 1 passed structures
  169. SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids
  170. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern
  171. The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters
  172. Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry
  173. Metabolically Improved Stem Cell Derived Hepatocyte-Like Cells Support HBV Life Cycle and Are a Promising Tool for HBV Studies and Antiviral Drug Screenings
  174. Advances and gaps in SARS-CoV-2 infection models
  175. Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches
  176. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern
  177. Antiviral Strategies Against (Non‐polio) Picornaviruses
  178. Antiviral Targets and Strategies to Treat and Prevent Human Norovirus Infections
  179. An affinity-enhanced, broadly neutralizing heavy chain–only antibody protects against SARS-CoV-2 infection in animal models
  180. Evaluation of the anti-SARS-CoV-2 properties of essential oils and aromatic extracts.
  181. The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern
  182. Comparative analysis of the molecular mechanism of resistance to vapendavir across a panel of picornavirus species
  183. Clinical practices underlie COVID-19 patient respiratory microbiome composition and its interactions with the host
  184. The legacy of ZikaPLAN: a transnational research consortium addressing Zika
  185. Publisher Correction: A pan-serotype dengue virus inhibitor targeting the NS3–NS4B interaction
  186. A pan-serotype dengue virus inhibitor targeting the NS3–NS4B interaction
  187. A highly potent antibody effective against SARS-CoV-2 variants of concern
  188. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model
  189. 1,2,4-Triazolo[1,5-a]pyrimidines: Efficient one-step synthesis and functionalization as influenza polymerase PA-PB1 interaction disruptors
  190. Discovery of a Novel Class of Norovirus Inhibitors with High Barrier of Resistance
  191. Assessing In Vitro Resistance Development in Enterovirus A71 in the Context of Combination Antiviral Treatment
  192. A Novel Class of Norovirus Inhibitors Targeting the Viral Protease with Potent Antiviral Activity In Vitro and In Vivo
  193. Broad betacoronavirus neutralization by a stem helix–specific human antibody
  194. Animal experiments show impact of vaccination on reduction of SARS-CoV-2 virus circulation: A model for vaccine development?
  195. Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues
  196. Identification and evaluation of potential SARS-CoV-2 antiviral agents targeting mRNA cap guanine N7-Methyltransferase
  197. Structure–Activity Relationship Studies on Novel Antiviral Agents for Norovirus Infections
  198. A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents
  199. A novel therapeutic HBV vaccine candidate induces strong polyfunctional cytotoxic T cell responses in mice
  200. Current and Future Antiviral Strategies to Tackle Gastrointestinal Viral Infections
  201. Broad sarbecovirus neutralization by a human monoclonal antibody
  202. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
  203. Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model
  204. Double Arylation of the Indole Side Chain of Tri- and Tetrapodal Tryptophan Derivatives Renders Highly Potent HIV-1 and EV-A71 Entry Inhibitors
  205. Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity
  206. Corrigendum to “itraconazole for COVID-19: Preclinical studies and a proof-of-concept randomized clinical trial Laurens”
  207. Structural Insights into the Mechanisms of Action of Functionally Distinct Classes of Chikungunya Virus Nonstructural Protein 1 Inhibitors
  208. Discovery of novel furo[2,3‐ d ]pyrimidin‐2‐one–1,3,4‐oxadiazole hybrid derivatives as dual antiviral and anticancer agents that induce apoptosis
  209. Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters
  210. Multivalent Tryptophan‐ and Tyrosine‐Containing [60]Fullerene Hexa‐Adducts as Dual HIV and Enterovirus A71 Entry Inhibitors
  211. COVID-19 and the intensive care unit: vaccines to the rescue
  212. In vitro activity of itraconazole against SARS‐CoV‐2
  213. Anticancer pan-ErbB inhibitors reduce inflammation and tissue injury and exert broad-spectrum antiviral effects
  214. Chemical Evolution of Antivirals Against Enterovirus D68 through Protein‐Templated Knoevenagel Reactions
  215. ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model
  216. Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2
  217. Alpha variant versus D614G strain in the Syrian hamster model
  218. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
  219. Infection of zebrafish larvae with human norovirus and evaluation of the in vivo efficacy of small-molecule inhibitors
  220. Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial
  221. Repurposing Drugs for Mayaro Virus: Identification of EIDD-1931, Favipiravir and Suramin as Mayaro Virus Inhibitors
  222. A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents
  223. High dimensional profiling identifies specific immune types along the recovery trajectories of critically ill COVID19 patients
  224. Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen
  225. Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2
  226. Kobophenol A Inhibits Binding of Host ACE2 Receptor with Spike RBD Domain of SARS-CoV-2, a Lead Compound for Blocking COVID-19
  227. Recent African strains of Zika virus display higher transmissibility and fetal pathogenicity than Asian strains
  228. Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages
  229. Identification of host factors binding to dengue and Zika virus subgenomic RNA by efficient yeast three-hybrid screens of the human ORFeome
  230. Comparing immunogenicity and protective efficacy of the yellow fever 17D vaccine in mice
  231. Assessment of the anti-norovirus activity in cell culture using the mouse norovirus: Early mechanistic studies
  232. Assessment of the anti-norovirus activity in cell culture using the mouse norovirus: Identification of active compounds
  233. Screening and in vitro antiviral assessment of small molecules against fluorescent protein-expressing Bunyamwera virus in a cell-based assay using high-content imaging
  234. A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate
  235. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms
  236. STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters
  237. Rational design of highly potent broad-spectrum enterovirus inhibitors targeting the nonstructural protein 2C
  238. A dengue type 2 reporter virus assay amenable to high-throughput screening
  239. Diketo acids inhibit the cap-snatching endonuclease of several Bunyavirales
  240. SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging
  241. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity
  242. Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry
  243. Identification of TMEM106B as proviral host factor for SARS-CoV-2
  244. Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients
  245. Enterovirus Inhibition by Hinged Aromatic Compounds with Polynuclei
  246. Enhanced efficacy of endonuclease inhibitor baloxavir acid against orthobunyaviruses when used in combination with ribavirin
  247. A single-dose live-attenuated YF17D-vectored SARS-CoV2 vaccine candidate
  248. Establishing a Unified COVID-19 “Immunome”: Integrating Coronavirus Pathogenesis and Host Immunopathology
  249. A prospect on the use of antiviral drugs to control local outbreaks of COVID-19
  250. Small-molecule inhibitors of TBK1 serve as an adjuvant for a plasmid-launched live-attenuated yellow fever vaccine
  251. Reverse engineering synthetic antiviral amyloids
  252. Antiviral and Cytotoxic Activity of Different Plant Parts of Banana (Musa spp.)
  253. Medical treatment options for COVID-19
  254. Novel Class of Chikungunya Virus Small Molecule Inhibitors That Targets the Viral Capping Machinery
  255. STAT2 signaling as double-edged sword restricting viral dissemination but driving severe pneumonia in SARS-CoV-2 infected hamsters
  256. Antibacterial, Antifungal, Antiviral, and Anthelmintic Activities of Medicinal Plants of Nepal Selected Based on Ethnobotanical Evidence
  257. A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies
  258. The Development of RNA-KISS, a Mammalian Three-Hybrid Method to Detect RNA–Protein Interactions in Living Mammalian Cells
  259. Antiviral drug discovery against arthritogenic alphaviruses: Tools and molecular targets
  260. Rational modifications, synthesis and biological evaluation of new potential antivirals for RSV designed to target the M2-1 protein
  261. Mycophenolic Acid Has Intrinsic Antiviral Properties and Potentiates the Antiviral Effect of Ribavirin on Parainfluenza Virus
  262. Quinolinecarboxamides Inhibit the Replication of the Bovine Viral Diarrhea Virus by Targeting a Hot Spot for the Inhibition of Pestivirus Replication in the RNA-Dependent RNA Polymerase
  263. Identification of 2-(4-(Phenylsulfonyl)piperazine-1-yl)pyrimidine Analogues as Novel Inhibitors of Chikungunya Virus
  264. Anti-norovirus activity of C7-modified 4-amino-pyrrolo[2,1-f][1,2,4]triazine C-nucleosides
  265. Alpha-ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication Structure-based design, synthesis, and activity assessment
  266. GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 5: Entomological aspects
  267. Pan-viral protection against arboviruses by activating skin macrophages at the inoculation site
  268. Regioselective convergent synthesis of 2-arylidene thiazolo[3,2-a]pyrimidines as potential anti-chikungunya agents
  269. A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice
  270. Increased IL‐10‐producing regulatory T cells are characteristic of severe cases of COVID‐19
  271. Monocyte-Driven Atypical Cytokine Storm and Aberrant Neutrophil Activation as Key Mediators of COVID19 Disease Severity
  272. Itraconazole for COVID-19: Preclinical Studies and a Proof-of-Concept Pilot Clinical Study
  273. A SCAFFOLD SIMPLIFICATION STRATEGY LEADS TO A NOVEL GENERATION OF DUAL HUMAN IMMUNODEFICIENCY VIRUS AND ENTEROVIRUS-A71 ENTRY INHIBITORS
  274. Design, synthesis and discovery of novel N,N’‐carbazoyl‐aryl‐urea inhibitors of Zika NS5 methyltransferase and virus replication
  275. Multitarget CFTR Modulators Endowed with Multiple Beneficial Side Effects for Cystic Fibrosis Patients: Toward a Simplified Therapeutic Approach
  276. 2019 meeting of the global virus network
  277. GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 2: Epidemiological distribution of o'nyong-nyong virus
  278. GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 3: Epidemiological distribution of Mayaro virus
  279. A new antiviral scaffold for human norovirus identified with computer-aided approaches on the viral polymerase
  280. Isolation of phenanthrenes and identification of phorbol ester derivatives as potential anti-CHIKV agents using FBMN and NAP from Sagotia racemosa
  281. A robust human norovirus replication model in zebrafish larvae
  282. Modifications in the branched arms of a class of dual inhibitors of HIV and EV71 replication expand their antiviral spectrum
  283. A chimeric Japanese encephalitis vaccine protects against lethal yellow fever virus infection without inducing neutralizing antibodies
  284. Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines
  285. New HSV-1 Anti-Viral 1′-Homocarbocyclic Nucleoside Analogs with an Optically Active Substituted Bicyclo[2.2.1]Heptane Fragment as a Glycoside Moiety
  286. A novel druggable interprotomer pocket in the capsid of rhino- and enteroviruses
  287. Viral engagement with host receptors blocked by a novel class of tryptophan dendrimers that targets the 5-fold-axis of the enterovirus-A71 capsid
  288. A Viral Polymerase Inhibitor Reduces Zika Virus Replication in the Reproductive Organs of Male Mice
  289. F-102 Antivirals, a lot has been achieved, yet a long way to go
  290. Pan-viral protection against arboviruses by targeting inoculation site-based skin macrophages
  291. GloPID-R report on Chikungunya, O'nyong-nyong and Mayaro virus, part I: Biological diagnostics
  292. Targeting the Viral Polymerase of Diarrhea-Causing Viruses as a Strategy to Develop a Single Broad-Spectrum Antiviral Therapy
  293. Structural and functional similarities in bunyaviruses: Perspectives for pan-bunya antivirals
  294. Antiviral effects of selected nucleoside analogues against human parechoviruses A1 and A3
  295. Antiviral Compounds from Codiaeum peltatum Targeted by a Multi-informative Molecular Networks Approach
  296. A robust human norovirus replication model in zebrafish larvae: Supplementary data file
  297. Scaffold Morphing Approach To Expand the Toolbox of Broad-Spectrum Antivirals Blocking Dengue/Zika Replication
  298. Progress in human picornavirus research: New findings from the AIROPico consortium
  299. Pyrimethamine inhibits rabies virus replication in vitro
  300. Intra-host emergence of an enterovirus A71 variant with enhanced PSGL1 usage and neurovirulence
  301. ZikaPLAN: addressing the knowledge gaps and working towards a research preparedness network in the Americas
  302. Limited evolution of the yellow fever virus 17d in a mouse infection model
  303. Human stem cell-derived hepatocyte-like cells support Zika virus replication and provide a relevant model to assess the efficacy of potential antivirals
  304. A yellow fever–Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in mice
  305. Favipiravir inhibits in vitro Usutu virus replication and delays disease progression in an infection model in mice
  306. CCL20, a direct-acting pro-angiogenic chemokine induced by hepatitis C virus (HCV): Potential role in HCV-related liver cancer
  307. Species Specificity of Type III Interferon Activity and Development of a Sensitive Luciferase-Based Bioassay for Quantitation of Mouse Interferon-λ
  308. Assessing medicinal plants traditionally used in the Chirang Reserve Forest, Northeast India for antimicrobial activity
  309. A Single-Dose Live-Attenuated Zika Virus Vaccine with Controlled Infection Rounds that Protects against Vertical Transmission
  310. PI4KIII inhibitor enviroxime impedes the replication of the hepatitis C virus by inhibiting PI3 kinases
  311. Discovery of Indole Derivatives as Novel and Potent Dengue Virus Inhibitors
  312. Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication
  313. HCV-induced EGFR-ERK signaling promotes a pro-inflammatory and pro-angiogenic signature contributing to liver cancer pathogenesis
  314. A Single Nucleoside Viral Polymerase Inhibitor Against Norovirus, Rotavirus, and Sapovirus-Induced Diarrhea
  315. Antiplasmodial, Anti-chikungunya virus and Antioxidant Activities of 64 endemic Plants from the Mascarene Islands
  316. Identification of fukinolic acid from Cimicifuga heracleifolia and its derivatives as novel antiviral compounds against enterovirus A71 infection
  317. Identification of Broad-Spectrum Dengue/Zika Virus Replication Inhibitors by Functionalization of Quinoline and 2,6-Diaminopurine Scaffolds
  318. Antiviral effect of the nucleoside analogue cidofovir in the context of sexual transmission of a gammaherpesvirus in mice
  319. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses
  320. Synthesis of Enantiomerically Pure 1′,2′-cis-dideoxy, -dideoxydi­dehydro, -ribo and -deoxy Carbocyclic Nucleoside Analogues
  321. Rational modifications on a benzylidene-acrylohydrazide antiviral scaffold, synthesis and evaluation of bioactivity against Chikungunya virus
  322. Recommendations for enterovirus diagnostics and characterisation within and beyond Europe
  323. Hepatitis E virus replication and interferonresponse in human placental-derived cells
  324. Differential antiviral activities of respiratory syncytial virus (RSV) inhibitors in human airway epithelium
  325. A reassessment of mycophenolic acid as a lead compound for the development of inhibitors of chikungunya virus replication
  326. Pan-NS3 protease inhibitors of hepatitis C virus based on an R 3 -elongated pyrazinone scaffold
  327. Structurally Diverse Diterpenoids from Sandwithia guyanensis
  328. Inhibition of the Replication of Different Strains of Chikungunya Virus by 3-Aryl-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones
  329. Design, synthesis and evaluation against Chikungunya virus of novel small-molecule antiviral agents
  330. Differential Antiviral Activities of RSV Inhibitors in Human Airway Epithelium
  331. Hepatitis E virus replication and interferon responses in human placental cells
  332. Antiviral treatment efficiently inhibits chikungunya virus infection in the joints of mice during the acute but not during the chronic phase of the infection
  333. Interferon lambda (IFN-λ) efficiently blocks norovirus transmission in a mouse model
  334. New Models to Study Hepatitis E Virus Replication and Particular Characteristics of Infection: The Needle Hides in the Hay Stack
  335. Rational design of antiviral drug combinations based on equipotency using HCV subgenomic replicon as an in vitro model
  336. Assessing the Efficacy of Small Molecule Inhibitors in a Mouse Model of Persistent Norovirus Infection
  337. The path towards effective antivirals against rabies
  338. Mannitol treatment is not effective in therapy of rabies virus infection in mice
  339. Heterocyclic pharmacochemistry of new rhinovirus antiviral agents: A combined computational and experimental study
  340. New class of early-stage enterovirus inhibitors with a novel mechanism of action
  341. Antimicrobial, Anthelmintic, and Antiviral Activity of Plants Traditionally Used for Treating Infectious Disease in the Similipal Biosphere Reserve, Odisha, India
  342. Novel therapeutic approaches to simultaneously target rhinovirus infection and asthma/COPD pathogenesis
  343. Upregulation of sodium taurocholate cotransporter polypeptide during hepatogenic differentiation of umbilical cord matrix mesenchymal stem cells facilitates hepatitis B entry
  344. Bioactive Natural Products Prioritization Using Massive Multi-informational Molecular Networks
  345. Replication of the Zika virus in different iPSC-derived neuronal cells and implications to assess efficacy of antivirals
  346. In silico development of a novel putative inhibitor of the 3C protease of Coxsackievirus B3 with a benzene sulfonamide skeleton
  347. Antiviral activity of [1,2,3]triazolo[4,5- d ]pyrimidin-7(6 H )-ones against chikungunya virus targeting the viral capping nsP1
  348. Fluorination of Naturally Occurring N6-Benzyladenosine Remarkably Increased Its Antiviral Activity and Selectivity
  349. Isolation of Premyrsinane, Myrsinane, and Tigliane Diterpenoids from Euphorbia pithyusa Using a Chikungunya Virus Cell-Based Assay and Analogue Annotation by Molecular Networking
  350. A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication
  351. A novel kindred with inherited STAT2 deficiency and severe viral illness
  352. Chikungunya virus infections: time to act, time to treat
  353. Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase
  354. Biological or pharmacological activation of protein kinase C alpha constrains hepatitis E virus replication
  355. Tiyoüreler, açiltiyoüreler ve 4-tiyazolidinonların sentezi, karakterizasyonu ve antikanser ve antiviral etkilerinin değerlendirilmesi
  356. Uncovering oxysterol-binding protein (OSBP) as a target of the anti-enteroviral compound TTP-8307
  357. Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery
  358. Glutathione is a highly efficient thermostabilizer of poliovirus Sabin strains
  359. Protein kinases C as potential host targets for the inhibition of chikungunya virus replication
  360. Structure-activity relationship studies on a Trp dendrimer with dual activities against HIV and enterovirus A71. Modifications on the amino acid
  361. Discovery of Multitarget Agents Active as Broad-Spectrum Antivirals and Correctors of Cystic Fibrosis Transmembrane Conductance Regulator for Associated Pulmonary Diseases
  362. Shape-based virtual screening, synthesis and evaluation of novel pyrrolone derivatives as antiviral agents against HCV
  363. ZikaPLAN: Zika Preparedness Latin American Network
  364. Aminopurine and aminoquinazoline scaffolds for development of potential dengue virus inhibitors
  365. Discovery of novel multi-target indole-based derivatives as potent and selective inhibitors of chikungunya virus replication
  366. In silico identification, design and synthesis of novel piperazine-based antiviral agents targeting the hepatitis C virus helicase
  367. Synthesis and in vitro antiviral evaluation of 4-substituted 3,4-dihydropyrimidinones
  368. In vitro Assay to Assess Efficacy of Potential Antiviral Compounds against Enterovirus D68
  369. Antiviral Agents Towards Chikungunya Virus: Structures, Syntheses, and Isolation from Natural Sources
  370. Effect of hepatitis E virus infection on the human hepatic innate immune response in human liver chimeric mice
  371. Biosafety standards for working with Crimean-Congo hemorrhagic fever virus
  372. Comparative analysis of the anti-chikungunya virus activity of novel bryostatin analogs confirms the existence of a PKC-independent mechanism
  373. Computer-aided identification, synthesis and evaluation of substituted thienopyrimidines as novel inhibitors of HCV replication
  374. Synthetic strategy and antiviral evaluation of diamide containing heterocycles targeting dengue and yellow fever virus
  375. Norovirus genetic diversity and evolution: implications for antiviral therapy
  376. Towards antiviral therapies for treating dengue virus infections
  377. Zika Virus Replicons for Drug Discovery
  378. Zika and Other Emerging Viruses: Aiming at the Right Target
  379. Hydantoin: The mechanism of its in vitro anti-enterovirus activity revisited
  380. Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity
  381. The viral capping enzyme nsP1: a novel target for the inhibition of chikungunya virus infection
  382. 9-Norbornyl-6-chloropurine (NCP) induces cell death through GSH depletion-associated ER stress and mitochondrial dysfunction
  383. Inhibition of human norovirus by a viral polymerase inhibitor in the B cell culture system and in the mouse model
  384. Post-exposure antiviral treatment of norovirus infections effectively protects against diarrhea and reduces virus shedding in the stool in a mortality mouse model
  385. Viral Macro Domains Reverse Protein ADP-Ribosylation
  386. A rat model for hepatitis E virus
  387. Update on hepatitis E virology: Implications for clinical practice
  388. Cover Image
  389. Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease
  390. Reply
  391. VP1 crystal structure-guided exploration and optimization of 4,5-dimethoxybenzene-based inhibitors of rhinovirus 14 infection
  392. Optimization of a Class of Tryptophan Dendrimers That Inhibit HIV Replication Leads to a Selective, Specific, and Low-Nanomolar Inhibitor of Clinical Isolates of Enterovirus A71
  393. Antiviral Activity of Favipiravir (T-705) against a Broad Range of ParamyxovirusesIn Vitroand against Human Metapneumovirus in Hamsters
  394. The Viral Polymerase Inhibitor 7-Deaza-2’-C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model
  395. 3-(imidazo[1,2- a :5,4- b ′]dipyridin-2-yl)aniline inhibits pestivirus replication by targeting a hot spot drug binding pocket in the RNA-dependent RNA polymerase
  396. Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver
  397. Modification of the length and structure of the linker of N6-benzyladenosine modulates its selective antiviral activity against enterovirus 71
  398. The viral polymerase inhibitor 7-deaza-2'-C-methyladenosine is a potent inhibitor of in 1 vitro Zika virus replication and delays disease progression in a robust mouse infection model
  399. Stem cell-derived hepatocytes: A novel model for hepatitis E virus replication
  400. Inhibition of Chikungunya Virus-Induced Cell Death by Salicylate-Derived Bryostatin Analogues Provides Additional Evidence for a PKC-Independent Pathway
  401. Simplified Bryostatin Analogues Protect Cells from Chikungunya Virus-Induced Cell Death
  402. Extra-hepatic replication and infection of hepatitis E virus in neuronal-derived cells
  403. Synthesis and Structure-Activity Relationships of Imidazole-Coumarin Conjugates against Hepatitis C Virus
  404. The Medicinal Chemistry of Dengue Virus
  405. Exploring the importance of zinc binding and steric/hydrophobic factors in novel HCV replication inhibitors
  406. Antiviral Strategies Against Chikungunya Virus
  407. Assessment of the activity of directly acting antivirals and other products against different genotypes of hepatitis C virus prevalent in resource-poor countries
  408. Identification and Analysis of Antiviral Compounds Against Poliovirus
  409. Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin
  410. PKCA/AP-1 Drives Transcription of Interferon-Stimulated Genes and Mediates Cell-Autonomous Defense against Hepatitis E Virus
  411. Treatment with a Nucleoside Polymerase Inhibitor Reduces Shedding of Murine Norovirus in Stool to Undetectable Levels without Emergence of Drug-Resistant Variants
  412. Novel symmetrical phenylenediamines as potential anti-hepatitis C virus agents
  413. The future of antivirals
  414. ID: 146
  415. Structure Elucidation of Coxsackievirus A16 in Complex with GPP3 Informs a Systematic Review of Highly Potent Capsid Binders to Enteroviruses
  416. Toward antiviral therapy/prophylaxis for rhinovirus-induced exacerbations of chronic obstructive pulmonary disease: challenges, opportunities, and strategies
  417. Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68
  418. Structure of Coxsackievirus A16 in complex with GPP3
  419. Towards antivirals against chikungunya virus
  420. LC-MS2-Based dereplication of Euphorbia extracts with anti-Chikungunya virus activity
  421. NMR-based conformational analysis of 2′,6-disubstituted uridines and antiviral evaluation of new phosphoramidate prodrugs
  422. Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity
  423. In vitro combinations containing Tegobuvir are highly efficient in curing cells from HCV replicon and in delaying/preventing the development of drug resistance
  424. Understanding the molecular mechanism of host-based statin resistance in hepatitis C virus replicon containing cells
  425. The microRNA-221/-222 cluster balances the antiviral and inflammatory response in viral myocarditis
  426. In vitro characterisation of a pleconaril/pirodavir-like compound with potent activity against rhinoviruses
  427. Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5-NS3 Interaction and the Host Src/Fyn Kinases
  428. Bicyclic and Tricyclic “Expanded” Nucleobase Analogues of Sofosbuvir: New Scaffolds for Hepatitis C Therapies
  429. The Enterovirus 3C Protease Inhibitor SG85 Efficiently Blocks Rhinovirus Replication and Is Not Cross-Resistant with Rupintrivir
  430. Benzouracil–coumarin–arene conjugates as inhibiting agents for chikungunya virus
  431. P200: Extrahepatic replication of hepatitis E virus in neuronal and placental cell lines
  432. HEV4 O-22: Human liver chimeric mice as a novel model for the study of hepatitis E virus infections
  433. P209: Near full-length hepatitis E virus genome sequencing analysis in a chronically infected patient following ribavirin treatment failure
  434. Tonantzitlolones from Stillingia lineata ssp. lineata as potential inhibitors of chikungunya virus
  435. Antiviral Activity of Diterpene Esters on Chikungunya Virus and HIV Replication
  436. Antiviral Activity of Flexibilane and Tigliane Diterpenoids from Stillingia lineata
  437. Broad-range inhibition of enterovirus replication by OSW-1, a natural compound targeting OSBP
  438. Molecular Chaperone Hsp90 Is a Therapeutic Target for Noroviruses
  439. Flaviviral NS4b, chameleon and jack‐in‐the‐box roles in viral replication and pathogenesis, and a molecular target for antiviral intervention
  440. Design, synthesis, optimization and antiviral activity of a class of hybrid dengue virus E protein inhibitors
  441. Crystal Structure of Coxsackie Virus B3 3D polymerase in complex with GPC-N114 inhibitor
  442. Crystal Structure of Coxsackievirus B3 3D polymerase in complex with GPC-N143
  443. Exploration of the anti-enterovirus activity of a series of pleconaril/pirodavir-like compounds
  444. I304V 3D polymerase mutant of EMCV
  445. M300V 3D polymerase mutant of EMCV
  446. P0488 : Dissecting the complexity of interferon response that cross talks with 4E-BP1 in hepatitis E virus infection
  447. P0692 : PKC/AP-1 signaling drives transcription of interferon-stimulated genes and exerts potent antiviral activity against hepatitis C and E viruses
  448. The RNA Template Channel of the RNA-Dependent RNA Polymerase as a Target for Development of Antiviral Therapy of Multiple Genera within a Virus Family
  449. Linear and branched alkyl-esters and amides of gallic acid and other (mono-, di- and tri-) hydroxy benzoyl derivatives as promising anti-HCV inhibitors
  450. Itraconazole Inhibits Enterovirus Replication by Targeting the Oxysterol-Binding Protein
  451. Bioengineering and Semisynthesis of an Optimized Cyclophilin Inhibitor for Treatment of Chronic Viral Infection
  452. Antiviral activity of cytokinin-like adenosine derivatives
  453. Reaching beyond HIV/HCV: nelfinavir as a potential starting point for broad-spectrum protease inhibitors against dengue and chikungunya virus
  454. New 1-phenyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides inhibit hepatitis C virus replication via suppression of cyclooxygenase-2
  455. Norbornane-based nucleoside and nucleotide analogues locked in North conformation
  456. A thiazepino[4,5-a]benzimidazole derivative hampers the RNA replication of Eurasian serotypes of foot-and-mouth disease virus
  457. Complete Genome Sequence of a Rat Hepatitis E Virus Strain Isolated in the United States
  458. A Mutation in the Hepatitis E Virus RNA Polymerase Promotes Its Replication and Associates With Ribavirin Treatment Failure in Organ Transplant Recipients
  459. Structure–activity relationship study of arbidol derivatives as inhibitors of chikungunya virus replication
  460. Synthesis and evaluation of imidazole-4,5- and pyrazine-2,3-dicarboxamides targeting dengue and yellow fever virus
  461. H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1
  462. Rapamycin and everolimus facilitate hepatitis E virus replication: Revealing a basal defense mechanism of PI3K-PKB-mTOR pathway
  463. Prophylactic treatment with the nucleoside analogue 2'-C-methylcytidine completely prevents transmission of norovirus
  464. The Capsid Binder Vapendavir and the Novel Protease Inhibitor SG85 Inhibit Enterovirus 71 Replication
  465. Norovirus: Targets and tools in antiviral drug discovery
  466. Tigliane diterpenes from Croton mauritianus as inhibitors of chikungunya virus replication
  467. A Refined Guinea Pig Model of Foot-and-Mouth Disease Virus Infection for Assessing the Efficacy of Antiviral Compounds
  468. A benzonitrile analogue inhibits rhinovirus replication
  469. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral
  470. A novel benzonitrile analogue inhibits rhinovirus replication
  471. Jatrophane Diterpenes as Inhibitors of Chikungunya Virus Replication: Structure–Activity Relationship and Discovery of a Potent Lead
  472. The Enterovirus Protease Inhibitor Rupintrivir Exerts Cross-Genotypic Anti-Norovirus Activity and Clears Cells from the Norovirus Replicon
  473. Calcineurin Inhibitors Stimulate and Mycophenolic Acid Inhibits Replication of Hepatitis E Virus
  474. From norbornane-based nucleotide analogs locked in South conformation to novel inhibitors of feline herpes virus
  475. Substituted 2,6-bis(benzimidazol-2-yl)pyridines: A novel chemical class of pestivirus inhibitors that targets a hot spot for inhibition of pestivirus replication in the RNA-dependent RNA polymerase
  476. Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C
  477. Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture
  478. Identification of [1,2,3]Triazolo[4,5-d]pyrimidin-7(6H)-ones as Novel Inhibitors of Chikungunya Virus Replication
  479. Are statins a viable option for the treatment of infections with the hepatitis C virus?
  480. In vitro surrogate models to aid in the development of antivirals for the containment of foot-and-mouth disease outbreaks
  481. Antiviral treatment of feline immunodeficiency virus-infected cats with (R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine
  482. Binding of Glutathione to Enterovirus Capsids Is Essential for Virion Morphogenesis
  483. New Pyrazolobenzothiazine Derivatives as Hepatitis C Virus NS5B Polymerase Palm Site I Inhibitors
  484. In search of Flavivirus inhibitors part 2: Tritylated, diphenylmethylated and other alkylated nucleoside analogues
  485. Synthesis, biological activity and structure–activity relationship of 4,5-dimethoxybenzene derivatives inhibitor of rhinovirus 14 infection
  486. O118 A MUTATION IN THE HEPATITIS E VIRUS POLYMERASE ASSOCIATED WITH RIBAVIRIN TREATMENT FAILURE HAS A REPLICATION ADVANTAGE IN VITRO
  487. P212 STEM CELL-DERIVED HEPATOCYTES AS A NOVEL IN VITRO MODEL TO STUDY HEPATOTROPIC VIRUSES
  488. Trigocherrierin A, a Potent Inhibitor of Chikungunya Virus Replication
  489. Synthesis of Novel Purine-Based Coxsackievirus Inhibitors Bearing Polycylic Substituents at the N-9 Position
  490. Application of a cell-based protease assay for testing inhibitors of picornavirus 3C proteases
  491. Antiviral strategies for hepatitis E virus
  492. Luminescence-based Antiviral Assay for Hepatitis E Virus
  493. Fitness and Virulence of a Coxsackievirus Mutant That Can Circumnavigate the Need for Phosphatidylinositol 4-Kinase Class III Beta
  494. Artemisinin Analogues as Potent Inhibitors of In Vitro Hepatitis C Virus Replication
  495. The Versatile Nature of the 6-Aminoquinolone Scaffold: Identification of Submicromolar Hepatitis C Virus NS5B Inhibitors
  496. Laboratory validation of a lateral flow device for the detection of CyHV-3 antigens in gill swabs
  497. Ribavirin InhibitsIn VitroHepatitis E Virus Replication through Depletion of Cellular GTP Pools and Is Moderately Synergistic with Alpha Interferon
  498. Antibody-dependent enhancement of dengue virus infection is inhibited by SA-17, a doxorubicin derivative
  499. Cutthroat trout virus as a surrogate in vitro infection model for testing inhibitors of hepatitis E virus replication
  500. The potential of antiviral agents to control classical swine fever: A modelling study
  501. The Viral Polymerase Inhibitor 2'-C-Methylcytidine Inhibits Norwalk Virus Replication and Protects against Norovirus-Induced Diarrhea and Mortality in a Mouse Model
  502. Identification of a new dengue virus inhibitor that targets the viral NS4B protein and restricts genomic RNA replication
  503. A Novel, Broad-Spectrum Inhibitor of Enterovirus Replication That Targets Host Cell Factor Phosphatidylinositol 4-Kinase IIIβ
  504. In search of flavivirus inhibitors: Evaluation of different tritylated nucleoside analogues
  505. 3-Biphenylimidazo[1,2-a]pyridines or [1,2-b]pyridazines and analogues, novel Flaviviridae inhibitors
  506. Exploration of the in vitro Antiviral Activity of a Series of New Pyrimidine Analogues on the Replication of HIV and HCV
  507. Molecular Biology and Inhibitors of Hepatitis A Virus
  508. Identification of a Series of Compounds with Potent Antiviral Activity for the Treatment of Enterovirus Infections
  509. Phosphatidylinositol 4-Kinase III Beta Is Essential for Replication of Human Rhinovirus and Its Inhibition Causes a Lethal PhenotypeIn Vivo
  510. Rapid and convenient assays to assess potential inhibitory activity on in vitro hepatitis A replication
  511. 3′,5′Di-O-trityluridine inhibits in vitro flavivirus replication
  512. Coumarins hinged directly on benzimidazoles and their ribofuranosides to inhibit hepatitis C virus
  513. Intra-host variation structure of classical swine fever virus NS5B in relation to antiviral therapy
  514. Intervention strategies for emerging viruses: use of antivirals
  515. Computer-aided identification, design and synthesis of a novel series of compounds with selective antiviral activity against chikungunya virus
  516. 1194 SYNERGISTIC COMBINATIONS OF ENTRY INHIBITORS WITH DACLATASVIR OR SOFOSBUVIR FOR PREVENTION AND TREATMENT OF CHRONIC HEPATITIS C
  517. Proof of Concept for the Inhibition of Foot-and-Mouth Disease Virus Replication by the Anti-Viral Drug 2′-C-Methylcytidine in Severe Combined Immunodeficient Mice
  518. Structure-Based Discovery of Pyrazolobenzothiazine Derivatives As Inhibitors of Hepatitis C Virus Replication
  519. Simple and inexpensive three-step rapid amplification of cDNA 5′ ends using 5′ phosphorylated primers
  520. 9-[2-(R)-(Phosphonomethoxy)propyl]-2,6-diaminopurine (R)-PMPDAP and its prodrugs: Optimized preparation, including identification of by-products formed, and antiviral evaluation in vitro
  521. 3C Protease of Enterovirus 68: Structure-Based Design of Michael Acceptor Inhibitors and Their Broad-Spectrum Antiviral Effects against Picornaviruses
  522. Selective Serotonin Reuptake Inhibitor Fluoxetine Inhibits Replication of Human Enteroviruses B and D by Targeting Viral Protein 2C
  523. Selecting and Characterizing Drug-Resistant Hepatitis C Virus Replicon
  524. Differentiated umbilical cord matrix stem cells as a newin vitromodel to study early events during hepatitis B virus infection
  525. Hepatitis C Virus-Specific Directly Acting Antiviral Drugs
  526. Erratum to “Human pluripotent stem cell-derived hepatocytes support complete replication of hepatitis C virus” [J Hepatol 2012;57:246–251]
  527. Safety Assessment in Pigs of an Experimental Molecule with In-Vitro Antiviral Activity Against African Swine Fever
  528. The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination
  529. Prostratin and 12-O-Tetradecanoylphorbol 13-Acetate Are Potent and Selective Inhibitors of Chikungunya Virus Replication
  530. Crucial role of the N-glycans on the viral E-envelope glycoprotein in DC-SIGN-mediated dengue virus infection
  531. The role of phosphatidylinositol 4-kinases and phosphatidylinositol 4-phosphate during viral replication
  532. Inhibition of norovirus replication by the nucleoside analogue 2′-C-methylcytidine
  533. Coxsackievirus mutants that can bypass host factor PI4KIIIβ and the need for high levels of PI4P lipids for replication
  534. Classical swine fever outbreak containment using antiviral supplementation: A potential alternative to emergency vaccination and stamping-out
  535. A novel method for high-throughput screening to quantify antiviral activity against viruses that induce limited CPE
  536. Favipiravir (T-705) inhibits in vitro norovirus replication
  537. Human pluripotent stem cell-derived hepatocytes support complete replication of hepatitis C virus
  538. 705 Stimulation of Angiogenesis by Hepatitis C Virus (HCV) Non-structural Proteins
  539. Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays
  540. The HCV Non-Nucleoside Inhibitor Tegobuvir Utilizes a Novel Mechanism of Action to Inhibit NS5B Polymerase Function
  541. Novel 1,2,4-triazole and imidazole derivatives of l-ascorbic and imino-ascorbic acid: Synthesis, anti-HCV and antitumor activity evaluations
  542. An Analogue of the Antibiotic Teicoplanin Prevents Flavivirus Entry In Vitro
  543. Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug
  544. Synthesis of novel thienonorbornylpurine derivatives
  545. 841 BC556, A POTENT, PAN-GENOTYPIC, HIGH BARRIER TO RESISTANCE, SECOND GENERATION CYCLOPHILIN INHIBITOR FOR TREATMENT OF CHRONIC HCV INFECTION
  546. 124 HEPATOCYTES DERIVED FROM HUMAN PLURIPOTENT STEM CELLS PERMIT COMPLETE REPLICATION OF THE HEPATITIS C VIRUS
  547. Efficient synthesis and anti-enteroviral activity of 9-arylpurines
  548. Novel substituted 9-norbornylpurines and their activities against RNA viruses
  549. Evaluation of the antiviral activity of (1′S,2′R)-9-[[1′,2′-bis(hydroxymethyl)cycloprop-1′-yl]methyl]guanine (A-5021) against equine herpesvirus type 1 in cell monolayers and equine nasal mucosal explants
  550. Sangamides, a new class of cyclophilin-inhibiting host-targeted antivirals for treatment of HCV infection
  551. Synthesis of novel azanorbornylpurine derivatives
  552. Combating enterovirus replication: State-of-the-art on antiviral research
  553. In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors
  554. Pyridobenzothiazole derivatives as new chemotype targeting the HCV NS5B polymerase
  555. Deletion of the vaccinia virus F13L gene results in a highly attenuated virus that mounts a protective immune response against subsequent vaccinia virus challenge
  556. Synthesis, Antiretroviral and Antioxidant Evaluation of a Series of New Benzo[b]furan Derivatives
  557. Antiviral Activity of Bay 41-4109 on Hepatitis B Virus in Humanized Alb-uPA/SCID Mice
  558. Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action
  559. Pharmacology and Mechanisms of Action of Antiviral Drugs: Polymerase Inhibitors
  560. The main Hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication
  561. Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication
  562. Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus
  563. Correction to 3′-Deoxy Phosphoramidate Dinucleosides as Improved Inhibitors of Hepatitis C Virus Subgenomic Replicon and NS5B Polymerase Activity
  564. Mechanistic Characterization of GS-9190 (Tegobuvir), a Novel Nonnucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase
  565. SAR studies of 9-norbornylpurines as Coxsackievirus B3 inhibitors
  566. Broad Antiviral Activity of Carbohydrate-Binding Agents against the Four Serotypes of Dengue Virus in Monocyte-Derived Dendritic Cells
  567. Comparative Study of the Genetic Barriers and Pathways towards Resistance of Selective Inhibitors of Hepatitis C Virus Replication
  568. Towards the design of combination therapy for the treatment of enterovirus infections
  569. European Training Network on (+)RNA Virus Replication and Antiviral Drug Development
  570. 3′,5′di-O-Trityluridine Inhibits Flavivirus (Dengue and Yellow Fever Virus) Replication and Targets the Viral RNA Dependent RNA Polymerase
  571. Classical Swine Fever Outbreak Containment – Antivirals as an Epidemiologically and Economically Viable Alternative to Emergency Vaccination and Culling
  572. Development of New Sulfur-Containing Conjugated Compounds as Anti-HCV Agents
  573. Phosphoramidate Dinucleosides as Inhibitors of Hepatitis C Virus Subgenomic Replicon and NS5B Polymerase Activity
  574. Viral Genome Dynamics During Antiviral Resistance Selection: A First Glimpse into Viral Evolution
  575. A Novel Method—Amenable for High-throughput Screening Purposes—to Quantify Antiviral Activity Against Viruses that Induce Limited CPE
  576. An Analogue of the Antibiotic Teicoplanin Inhibits Dengue Virus Entry In Vitro
  577. An Antiviral Assay to Identify Inhibitors of the Human Metapneumovirus that is Amenable for High-throughput Screening Purposes
  578. Computer-aided Design and Evaluation of Novel Anti-CHIKV Compounds
  579. Coumarins Hybridized with Heterocycles or Ribonucleosides for Eradication of Hepatitis C Virus
  580. In Vitro Combination Therapy with Tegobuvir (GS-9190) is Highly Efficient in Curing Cells from HCV Replicon and in Delaying/Preventing the Development of Antiviral Resistance
  581. Targeting the Flavivirus Helicase
  582. Coumarin−Purine Ribofuranoside Conjugates as New Agents against Hepatitis C Virus
  583. Diagnostic performance and application of two commercial cell viability assays in foot-and-mouth disease research
  584. Inhibition of hepatitis C virus replication by semi-synthetic derivatives of glycopeptide antibiotics
  585. Preclinical Characterization of Naturally Occurring Polyketide Cyclophilin Inhibitors from the Sanglifehrin Family
  586. Picornavirus non-structural proteins as targets for new anti-virals with broad activity
  587. 482 IN VITRO COMBINATION THERAPY WITH TEGOBUVIR (GS-9190) IS HIGHLY EFFICIENT IN CURING CELLS FROM HCV REPLICON AND IN DELAYING/PREVENTING THE DEVELOPMENT OF ANTIVIRAL RESISTANCE
  588. 789 PRECLINICAL CHARACTERIZATION OF NOVEL CYCLOPHILIN INHIBITORS BASED ON THE POLYKETIDE, SANGLIFEHRIN
  589. Adefovir serum levels do not differ between responders and nonresponders
  590. Conformationally locked nucleoside analogues based on the bridgehead substituted 7-oxonorbornane and their antiviral properties
  591. Highly potent and selective inhibition of bovine viral diarrhea virus replication by γ-carboline derivatives
  592. Straightforward synthesis of triazoloacyclonucleotide phosphonates as potential HCV inhibitors
  593. Short and efficient access to imidazo[1,2-a]pyrrolo[3,2-c]pyridine derivatives
  594. DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A
  595. Synthesis of Ester Prodrugs of 9-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as Anti-Poxvirus Agents
  596. Development of a Foot-and-Mouth Disease Infection Model in Severe Combined Immunodeficient Mice for the Preliminary Evaluation of Antiviral Drugs
  597. Hepatitis C Virus Infection of Neuroepithelioma Cell Lines
  598. 3′-Deoxy Phosphoramidate Dinucleosides as Improved Inhibitors of Hepatitis C Virus Subgenomic Replicon and NS5B Polymerase Activity
  599. A Derivate of the Antibiotic Doxorubicin Is a Selective Inhibitor of Dengue and Yellow Fever Virus Replication In Vitro
  600. Tracking the Evolution of Multiple In Vitro Hepatitis C Virus Replicon Variants under Protease Inhibitor Selection Pressure by 454 Deep Sequencing
  601. Structure and functionality in flavivirus NS-proteins: Perspectives for drug design
  602. Antiviral strategies to control calicivirus infections
  603. Genomics and structure/function studies of Rhabdoviridae proteins involved in replication and transcription
  604. Design, synthesis, and biological evaluation of novel coxsackievirus B3 inhibitors
  605. S-Aryltriazole acyclonucleosides: Synthesis and biological evaluation against hepatitis C virus
  606. Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections
  607. Differential Effects of the Putative GBF1 Inhibitors Golgicide A and AG1478 on Enterovirus Replication
  608. Synthesis and antiviral activity of an imidazo[1,2-a]pyrrolo[2,3-c]pyridine series against the bovine viral diarrhea virus
  609. A Novel 9-Arylpurine Acts as a Selective Inhibitor of In Vitro Enterovirus Replication Possibly by Targeting Virus Encapsidation
  610. Application of the phosphoramidate ProTide approach to the antiviral drug ribavirin
  611. In Vitro Selection and Characterization of Hepatitis C Virus Replicons Double or Triple Resistant to Various Non-nucleoside HCV Polymerase Inhibitors
  612. γ-Carboline Derivatives as Potent and Selective Inhibitors of Bovine Viral Diarrhea Virus (BVDV) Replication
  613. Synthesis of Ester Prodrugs of 9-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as Anti-Poxvirus Agents
  614. Eradication of Persistent Bovine Viral Diarrhea Virus Infection in Cell Culture by Antiviral Treatment: How to Get Ahead of the Viral Evasion Strategy
  615. Inhibition of Hepatitis C Virus Replication by Semisynthetic Derivatives of Glycopeptide Antibiotics
  616. Antiviral Therapy for Hepatitis C Virus: Beyond the Standard of Care
  617. Replication of not-known-vector flaviviruses in mosquito cells is restricted by intracellular host factors rather than by the viral envelope proteins
  618. Synthesis and antiviral activity of boranophosphonate isosteres of AZT and d4T monophosphates
  619. 9-Arylpurines as a Novel Class of Enterovirus Inhibitors
  620. Synthesis of novel racemic carbocyclic nucleosides derived from 5,6-disubstituted norbornene
  621. Reply:
  622. Norbornane as the novel pseudoglycone moiety in nucleosides
  623. The reduction of CSFV transmission to untreated pigs by the pestivirus inhibitor BPIP: A proof of concept
  624. Identification of allosteric inhibitors blocking the hepatitis C virus polymerase NS5B in the RNA synthesis initiation step
  625. Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A
  626. The phosphoramidate ProTide approach greatly enhances the activity of β-2′-C-methylguanosine against hepatitis C virus
  627. Cu-Mediated SelectiveN-Arylation of Aminotriazole Acyclonucleosides
  628. Synthesis and Antiviral Evaluation of 2′-C-Methyl Analogues of 5-Alkynyl- and 6-Alkylfurano- and Pyrrolo[2,3-d]Pyrimidine Ribonucleosides
  629. A pyrazolotriazolopyrimidinamine inhibitor of bovine viral diarrhea virus replication that targets the viral RNA-dependent RNA polymerase
  630. Discovery of a novel HCV helicase inhibitor by a de novo drug design approach
  631. Inhibition of Subgenomic Hepatitis C Virus RNA Replication by Acridone Derivatives: Identification of an NS3 Helicase Inhibitor
  632. Antiviral Activity of Carbohydrate Binding Agents (CBAS) and the Role of DC-SIGN in Dengue Virus and HIV Infection
  633. Comparative Study of the Genetic Barrier and Pathways Towards Resistance of Selective Inhibitors of HCV Replication
  634. In vitro Anti-hepatitis C Virus (HCV) Activities and Resistance Profile of Debio 025, A Non-immunosuppressive Cyclophilin Binding Molecule
  635. Novel 9-Arylpurines, as Selective Inhibitors of In Vitro Enterovirus Replication
  636. Phosphoramidate Protides Greatly Enhance the Anti-HCV Activity of 2′-Methylguanosine
  637. Substituted imidazopyridines as potent inhibitors of HCV replication
  638. Synthesis and SAR of 9-Arylpurines as Novel Inhibitors of Enterovirus Replication
  639. Antiviral activity of carbohydrate-binding agents and the role of DC-SIGN in dengue virus infection
  640. Inflammatory rather than infectious insults play a role in exocrine tissue damage in a mouse model for coxsackievirus B4-induced pancreatitis
  641. 88 PARTICULAR IN VITRO ANTI-HCV ACTIVITIES AND RESISTANCE PROFILE OF THE CYCLOPHILIN INHIBITOR DEBIO 025
  642. Structure−Activity Relationship of New Anti-Hepatitis C Virus Agents: Heterobicycle−Coumarin Conjugates
  643. Proof of concept for the reduction of classical swine fever infection in pigs by a novel viral polymerase inhibitor
  644. Discovery of Novel Arylethynyltriazole Ribonucleosides with Selective and Effective Antiviral and Antiproliferative Activity
  645. Mutations in the Nonstructural Protein 3A Confer Resistance to the Novel Enterovirus Replication Inhibitor TTP-8307
  646. Statins potentiate thein vitroanti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development
  647. ChemInform Abstract: Selective Inhibitors of Picornavirus Replication
  648. Antiviral Agents Acting as DNA or RNA Chain Terminators
  649. Synthesis of novel carbocyclic nucleoside analogues derived from 7-oxabicyclo[2.2.1]heptane-2-methanol
  650. Synthesis of novel racemic carbocyclic nucleoside analogues derived from 4,8-dioxatricyclo[4.2.1.03,7]nonane-9-methanol and 4-oxatricyclo[4.3.1.03,7]decane-10-methanol, compounds with activity against Coxsackie viruses
  651. Studies of antiviral activity and cytotoxicity ofWrightia tinctoriaandMorinda citrifolia
  652. Debio 025, a Cyclophilin Binding Molecule, Is Highly Efficient in Clearing Hepatitis C Virus (HCV) Replicon-Containing Cells When Used Alone or in Combination with Specifically Targeted Antiviral Therapy for HCV (STAT-C) Inhibitors
  653. Increased gelatinase B/matrix metalloproteinase 9 (MMP-9) activity in a murine model of acute coxsackievirus B4-induced pancreatitis
  654. Comparisons of the influenza virus A M2 channel binding affinities, anti-influenza virus potencies and NMDA antagonistic activities of 2-alkyl-2-aminoadamantanes and analogues
  655. Selective inhibitors of picornavirus replication
  656. Mouse and Hamster Models for the Study of Therapy against Flavivirus Infections
  657. Intracellular metabolism of the new antiviral compound 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine
  658. Phosphoramidate Dinucleosides as Hepatitis C Virus Polymerase Inhibitors
  659. Assessing the Efficacy of Cidofovir against Herpesvirus-Induced Genital Lesions in Goats Using Different Therapeutic Regimens
  660. A case for developing antiviral drugs against polio
  661. Synthesis and anti-CVB 3 evaluation of substituted 5-nitro-2-phenoxybenzonitriles
  662. Synthesis and antiviral activity of novel derivatives of 2'- -C-methylcytidine
  663. The Crystal Structure of Coxsackievirus B3 RNA-Dependent RNA Polymerase in Complex with Its Protein Primer VPg Confirms the Existence of a Second VPg Binding Site on Picornaviridae Polymerases
  664. Comparative In Vitro Anti-Hepatitis C Virus Activities of a Selected Series of Polymerase, Protease, and Helicase Inhibitors
  665. Arylethynyltriazole acyclonucleosides inhibit hepatitis C virus replication
  666. R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond
  667. A Derivate of the Antibiotic Doxorubicin Inhibits Dengue and Yellow Fever Virus Replication In Vitro
  668. Application of the Phosphoramidate Protide Approach to the Antiviral Drug Ribavirin
  669. Discovery of a Novel HCV Helicase Inhibitor by a De Novo Drug Design Approach
  670. Mevastatin Markedly Potentiates the Anti-HCV Activity of Selective Inhibitors of HCV Replication and Delays or Prevents the Emergence of Antiviral Resistance
  671. Synthesis and Antiviral Activity of Various N4-Acyl Derivatives of Cidofovir and its 5-Azacytosine Counterpart, 1-(S)-[3-Hydroxy-2-(Phosphonomethoxy)Propyl]-5-Azacytosine
  672. Treatment of yellow fever
  673. The VIZIER project: Preparedness against pathogenic RNA viruses
  674. Animal models of highly pathogenic RNA viral infections: Encephalitis viruses
  675. Animal models of highly pathogenic RNA viral infections: Hemorrhagic fever viruses
  676. Current and future antiviral therapy of severe seasonal and avian influenza
  677. Does antiviral therapy have a role in the control of Japanese encephalitis?
  678. FDA perspective on antivirals against biothreats: Communicate early and often
  679. Highly pathogenic RNA viral infections: Challenges for antiviral research
  680. International research networks in viral structural proteomics: Again, lessons from SARS
  681. Molecular strategies to inhibit the replication of RNA viruses
  682. NIAID resources for developing new therapies for severe viral infections
  683. New opportunities for field research on the pathogenesis and treatment of Lassa fever
  684. Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA viruses
  685. Potential of antiviral therapy and prophylaxis for controlling RNA viral infections of livestock
  686. The Southeast Asian Influenza Clinical Research Network: Development and challenges for a new multilateral research endeavor
  687. Treatment of Argentine hemorrhagic fever
  688. Treatment of Crimean-Congo hemorrhagic fever
  689. Treatment of Marburg and Ebola hemorrhagic fevers: A strategy for testing new drugs and vaccines under outbreak conditions
  690. Treatment of hantavirus pulmonary syndrome
  691. Potential Use of Antiviral Agents in Polio Eradication
  692. Suboptimal Response to Adefovir Dipivoxil Therapy for Chronic Hepatitis B in Nucleoside-Naive Patients is not due to Pre-Existing Drug-Resistant Mutants
  693. The Thiazolobenzimidazole TBZE-029 Inhibits Enterovirus Replication by Targeting a Short Region Immediately Downstream from Motif C in the Nonstructural Protein 2C
  694. Imidazo[4,5-c]pyridines inhibit the in vitro replication of the classical swine fever virus and target the viral polymerase
  695. Synthesis of new benzimidazole–coumarin conjugates as anti-hepatitis C virus agents
  696. Inhibition of Human Immunodeficiency Virus Type 1 Replication in Human Cells by Debio-025, a Novel Cyclophilin Binding Agent
  697. In vitro antiviral activity of some novel isatin derivatives against HCV and SARS-CoV viruses
  698. Evaluation of Hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)Propyl]-Adenine, CMX157, as a Potential Treatment for Human Immunodeficiency Virus Type 1 and Hepatitis B Virus Infections
  699. Alkyne-Azide Click Chemistry Mediated Carbanucleosides Synthesis
  700. Cross-Metathesis Mediated Synthesis of New Acyclic Nucleoside Phosphonates
  701. New Analogs of Acyclovir Substituted at the Side Chain
  702. Ester Prodrugs of Cyclic 1-(S)- [3-Hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine:  Synthesis and Antiviral Activity
  703. Antiviral 2,5-disubstituted imidazo[4,5-c]pyridines: Further optimization of anti-hepatitis C virus activity
  704. The Imidazopyrrolopyridine Analogue AG110 Is a Novel, Highly Selective Inhibitor of Pestiviruses That Targets the Viral RNA-Dependent RNA Polymerase at a Hot Spot for Inhibition of Viral Replication
  705. Conservation of the pentanucleotide motif at the top of the yellow fever virus 17D 3' stem-loop structure is not required for replication
  706. Potent Inhibition of Genital Herpesvirus Infection in Goats by Cidofovir
  707. Evaluation of Hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)Propyl]- Adenine, CMX157, as a Potential Treatment for Human Immunodeficiency Virus Type 1 and Hepatitis B Virus Infections
  708. Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention
  709. Comparative Activity of Anti-Enteroviral Agents Against Poliovirus Replication In VitroImplications For the End Phase of the Polio Eradication Initiative
  710. Conservation of the pentanucleotide motif at the top of the yellow fever virus 17D 3' stem-loop structure is not required for replication
  711. Enhanced Antiviral Activity of Hexadecyloxypropyl-PME-N6-Cyclopropyl-diaminopurine Against Herpesviruses, Hepatitis B Virus and Vaccinia Virus, In Vitro
  712. In Vivo Antiviral Activity of 1-(S)-[3-Hydroxy-2-(Phosphonomethoxy)Propyl]-5-Azacytosine and its Cyclic Form
  713. Substituted Imidazopyridines as Potent Inhibitors of Hepatitis C Virus Replication that Target the Viral Polymerase
  714. Synthesis and antiviral activities of new acyclic and “double-headed” nucleoside analogues
  715. Synthesis and Antiviral Activity of 1-(S)-[3-Hydroxy-2-(Phosphonomethoxy)Propyl]-5-Azacytosine and its Ester Prodrugs
  716. Synthesis of Novel Types of Anti-Coxsackie Virus Compounds
  717. The Cyclophilin Inhibitor Debio-025 is a Potent Inhibitor of Hepatitis C Virus Replication in vitro With a Unique Resistance Profile
  718. The Imidazopyrrolopyridine Analogue AG110 is a Novel, Highly Selective Inhibitor of Pestivirus Replication and Targets the viral RNA-dependent RNA Polymerase
  719. Thiazolobenzimidazoles, a Novel Class of Enterovirus Inhibitors, Target the 2C Protein
  720. In vitro susceptibility of six isolates of equine herpesvirus 1 to acyclovir, ganciclovir, cidofovir, adefovir, PMEDAP and foscarnet
  721. Improved crystallization of the coxsackievirus B3 RNA-dependent RNA polymerase
  722. Cidofovir is effective against caprine herpesvirus 1 infection in goats
  723. In Vitro Activity of 2,4-Diamino-6-[2-(Phosphonomethoxy)Ethoxy]-Pyrimidine against Multidrug-Resistant Hepatitis B Virus Mutants
  724. 2′-C-Methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus
  725. Ribavirin and mycophenolic acid markedly potentiate the anti-hepatitis B virus activity of entecavir
  726. Antiviral Activity of Triazine Analogues of 1-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine (Cidofovir) and Related Compounds
  727. Anti-enterovirus activity and structure–activity relationship of a series of 2,6-dihalophenyl-substituted 1H,3H-thiazolo[3,4-a]benzimidazoles
  728. Influence of an additional 2-amino substituent of the 1-aminoethyl pharmacophore group on the potency of rimantadine against influenza virus A
  729. Substituted 5-Benzyl-2-phenyl-5H-imidazo[4,5-c]pyridines: A New Class of Pestivirus Inhibitors.
  730. Synthesis of 5-Aryltriazole Ribonucleosides via Suzuki Coupling and Promoted by Microwave Irradiation.
  731. 239 EMBRYOTOXICITY ASSAY FOR ANTIVIRAL COMPOUND BPIP (5-[(4-BROMOPHENYL)METHYL]-2-PHENYL-5H-IMIDAZO[4,5-c]PYRIDINE) IN BOVINE IN VITRO -PRODUCED EMBRYOS
  732. Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future
  733. Antiviral 2,5-disubstituted imidazo[4,5-c]pyridines: From anti-pestivirus to anti-hepatitis C virus activity
  734. Synthesis, in Vitro Antiviral Evaluation, and Stability Studies of Novel α-Borano-Nucleotide Analogues of 9-[2-(Phosphonomethoxy)ethyl]adenine and (R)-9-[2-(Phosphonomethoxy)propyl]adenine
  735. Ribavirin Antagonizes the In Vitro Anti-Hepatitis C Virus Activity of 2′-C-Methylcytidine, the Active Component of Valopicitabine
  736. Substituted 5-benzyl-2-phenyl-5H-imidazo[4,5-c]pyridines: A new class of pestivirus inhibitors
  737. Synthesis, conformational characteristics and anti-influenza virus A activity of some 2-adamantylsubstituted azacycles
  738. Hepatitis B virus replication causes oxidative stress in HepAD38 liver cells
  739. Selective inhibitors of hepatitis C virus replication
  740. Hemin potentiates the anti-hepatitis C virus activity of the antimalarial drug artemisinin
  741. Introduction to the Special Issue dedicated to Prof. Erik De Clercq for reaching the Professor Emeritus status at the Katholieke Universiteit Leuven
  742. Synthesis of 5-aryltriazole ribonucleosides via Suzuki coupling and promoted by microwave irradiation
  743. Inhibition of Urokinase-Type Plasminogen Activator or Matrix Metalloproteinases Prevents Cardiac Injury and Dysfunction During Viral Myocarditis
  744. Synthesis of 6-Arylthio Analogs of 2′,3′-Dideoxy-3′-Fluoroguanosine and Their Effect against Hepatitis B Virus Replication
  745. Clinical effect of cidofovir and a diet supplemented with Spirulina platensis in white spot syndrome virus (WSSV) infected specific pathogen-free Litopenaeus vannamei juveniles
  746. Poly(I)-Poly(C12U) but Not Ribavirin Prevents Death in a Hamster Model of Nipah Virus Infection
  747. Heterocyclic rimantadine analogues with antiviral activity
  748. Acute Encephalitis, a Poliomyelitis-like Syndrome and Neurological Sequelae in a Hamster Model for Flavivirus Infections
  749. Synthesis and Anti-BVDV Activity of Acridones As New Potential Antiviral Agents1
  750. The Anti-Yellow Fever Virus Activity of Ribavirin Is Independent of Error-Prone Replication
  751. A Novel, Highly Selective Inhibitor of Pestivirus Replication That Targets the Viral RNA-Dependent RNA Polymerase
  752. Selective inhibitors of the replication of poxviruses
  753. P.091 Selection and phenotypic characterization of multiple drug resistant variants in patients with chronic hepatitis B
  754. Synthesis and Antiviral Evaluation of Cyclic and Acyclic 2-Methyl-3-hydroxy-4-pyridinone Nucleoside Derivatives
  755. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replicationin vitro
  756. Viral load quantitation of SARS-coronavirus RNA using a one-step real-time RT-PCR
  757. Preliminary report of anti-hepatitis C virus activity of chloroquine and hydroxychloroquine in huh-5-2 cell line
  758. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection
  759. Synthesis and primary antiviral activity evaluation of 3-hydrazono-5-nitro-2-indolinone derivatives
  760. Corrigendum to “Selective inhibition of hepatitis B virus replication by RNA interference” [Biochem. Biophys. Res. Commun. 309 (2003) 482–484]
  761. An Orally Bioavailable Antipoxvirus Compound (ST-246) Inhibits Extracellular Virus Formation and Protects Mice from Lethal Orthopoxvirus Challenge
  762. ANTIVIRAL POTENTIAL OF A NEW GENERATION OF ACYCLIC NUCLEOSIDE PHOSPHONATES, THE 6-[2-(PHOSPHONOMETHOXY)ALKOXY]-2,4-DIAMINOPYRIMIDINES
  763. Growth kinetics of SARS-coronavirus in Vero E6 cells
  764. Novel Acyclic Nucleoside Phosphonate Analogues with Potent Anti-Hepatitis B Virus Activities
  765. The Predominant Mechanism by Which Ribavirin Exerts Its Antiviral Activity In Vitro against Flaviviruses and Paramyxoviruses Is Mediated by Inhibition of IMP Dehydrogenase
  766. Synthesis and Antiviral Evaluation of Cis-Substituted Cyclohexenyl and Cyclohexanyl Nucleosides
  767. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine
  768. Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections
  769. Rodent models for the study of therapy against flavivirus infections
  770. Rodent models for the study of therapy against flavivirus infections
  771. Exchanging the Yellow Fever Virus Envelope Proteins with Modoc Virus prM and E Proteins Results in a Chimeric Virus That Is Neuroinvasive in SCID Mice
  772. Efficacy of Cidofovir in a Murine Model of Disseminated Progressive Vaccinia
  773. Evaluation of antiviral activity against human herpesvirus 8 (HHV-8) and Epstein–Barr virus (EBV) by a quantitative real-time PCR assay
  774. Antiviral drugs in current clinical use
  775. The Interferon Inducer Ampligen [Poly(I)-Poly(C12U)] Markedly Protects Mice against Coxsackie B3 Virus-Induced Myocarditis
  776. In vivomonitoring of acute flavivirus (Modoc) encephalitis with regional and whole-brain quantitative diffusion magnetic resonance imaging
  777. Heterocyclic rimantadine analogues with antiviral activity
  778. Synthesis and antiviral evaluation of 3-hydroxy-2-methylpyridin-4-one dideoxynucleoside derivatives
  779. Synthesis and Antiviral Evaluation of Ribavirin Congeners Containing a Hexitol Moiety
  780. Selective Inhibitors of Hepatitis B Virus Replication
  781. Selective inhibition of hepatitis B virus replication by RNA interference
  782. The acyclic nucleoside phosphonate analogues, adefovir, tenofovir and PMEDAP, efficiently eliminate banana streak virus from banana (Musa spp.)
  783. Are the 2-Isomers of the Drug Rimantadine Active Anti-Influenza a Agents?
  784. Spiro[pyrrolidine-2,2′-adamantanes]: synthesis, anti-influenza virus activity and conformational properties
  785. A rapid and convenient variant of fusion-PCR to construct chimeric flaviviruses
  786. Interferons, Interferon Inducers, and Interferon-Ribavirin in Treatment of Flavivirus-Induced Encephalitis in Mice
  787. Ribavirin Derivatives with a Hexitol Moiety: Synthesis and Antiviral Evaluation
  788. Inhibition of coxsackie B3 virus induced myocarditis in mice by 2-(3,4-dichlorophenoxy)-5-nitrobenzonitrile
  789. Impact of Direct Virus-Induced Neuronal Dysfunction and Immunological Damage on the Progression of Flavivirus (Modoc) Encephalitis in a Murine Model
  790. Prospects for Antiviral Therapy
  791. Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives
  792. Impact of Direct Virus-Induced Neuronal Dysfunction and Immunological Damage on the Progression of Flavivirus (Modoc) Encephalitis in a Murine Model
  793. Human Herpesvirus 8 Gene Encodes a Functional Thymidylate Synthase
  794. Gammaherpesviruses encode functional dihydrofolate reductase activity
  795. Genome sequence analysis of Tamana bat virus and its relationship with the genus Flavivirus
  796. Effect of 5-Iodo-2′-Deoxyuridine on Vaccinia Virus (Orthopoxvirus) Infections in Mice
  797. 2-chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections
  798. Complete genome sequence of Montana Myotis leukoencephalitis virus, phylogenetic analysis and comparative study of the 3′ untranslated region of flaviviruses with no known vector
  799. Infection of SCID mice with Montana Myotis leukoencephalitis virus as a model for flavivirus encephalitis
  800. Antiviral and immunomodulatory activity of the metal chelator ethylenediaminedisuccinic acid against cytomegalovirus in vitro and in vivo
  801. Sulphated and Sulphonated Polymers Inhibit the Initial Interaction of Hepatitis B Virus with Hepatocytes
  802. Complete Genome Sequence, Taxonomic Assignment, and Comparative Analysis of the Untranslated Regions of the Modoc Virus, a Flavivirus with No Known Vector
  803. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties
  804. In vitro Activity of Polyhydroxycarboxylates against Herpesviruses and Hiv
  805. Carrier-Mediated Delivery Improves the Efficacy of 9-(2-Phosphonylmethoxyethyl)Adenine against Hepatitis B Virus
  806. Novel 3-(2-Adamantyl)pyrrolidines with potent activity against influenza A virus—identification of aminoadamantane derivatives bearing two pharmacophoric amine groups
  807. A chemiluminescence detection method of hantaviral antigens in neutralisation assays and inhibitor studies
  808. ACYCLIC/CARBOCYCLIC GUANOSINE ANALOGUES AS ANTI-HERPESVIRUS AGENTS
  809. Angiogenesis: regulators and clinical applications
  810. Anti-herpesvirus activity of (1′S,2′R)-9-[[1′,2′-bis(hydroxymethyl)-cycloprop-1′-yl]methyl]guanine (A-5021) in vitro and in vivo
  811. The anti-herpesvirus activity of (1′S,2′R)-9-[[1′,2′-bis(hydroxymethyl)cycloprop-1′-yl]methyl]guanine is markedly potentiated by the immunosuppressive agent mycophenolate mofetil
  812. Efficacy of 2-Amino-7-(1,3-Dihydroxy-2-Propoxymethyl)Purine for Treatment of Vaccinia Virus (Orthopoxvirus) Infections in Mice
  813. A Novel Model for the Study of the Therapy of Flavivirus Infections Using the Modoc Virus
  814. Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8
  815. Effect of TNP-470 (AGM-1470) on the Growth of Rat Rhabdomyosarcoma Tumors of Different Sizes
  816. Potent inhibition of hemangiosarcoma development in mice by cidofovir
  817. Ribavirin and mycophenolic acid potentiate the activity of guanine- and diaminopurine-based nucleoside analogues against hepatitis B virus
  818. Use of Cotton Rats to Evaluate the Efficacy of Antivirals in Treatment of Measles Virus Infections
  819. Hydrogels containing monocaprin prevent intravaginal and intracutaneous infections with HSV-2 in mice: Impact on the search for vaginal microbicides
  820. Antiviral activity of ganciclovir elaidic acid ester against herpesviruses
  821. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir
  822. Perspectives for the Treatment of Infections with Flaviviridae
  823. Perspectives for the Treatment of Infections withFlaviviridae
  824. Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture
  825. Hydroxyurea Potentiates the Antiherpesvirus Activities of Purine and Pyrimidine Nucleoside and Nucleoside Phosphonate Analogs
  826. Synthesis and Antiviral and Cytostatic Activities of Carbocyclic Nucleosides Incorporating a Modified Cyclobutane Ring
  827. Budding Yeast as a Screening Tool for Discovery of Nucleoside Analogs for Use in HSV-1 TK Suicide-Gene Therapy
  828. Use of digoxigenin-labelled probes for the quantitation of HBV-DNA in antiviral drug evaluation
  829. Modulation of Fibroblast Growth Factor-2 Receptor Binding, Signaling, and Mitogenic Activity by Heparin-Mimicking Polysulfonated Compounds
  830. Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro
  831. Potent inhibition of human cytomegalovirus (HCMV) replication by alkenyl guanine analogs with a thiazole[4,5-d]pyrimidine ring
  832. Antitumor Potential of Acyclic Nucleoside Phosphonates
  833. THE IMMUNOSUPPRESSIVE AGENT MYCOPHENOLATE MOFETIL MARKEDLY POTENTIATES THE ACTIVITY OF LOBUCAVIR [1R(1??,2??,3??)]-9-[2,3-BIS(HYDROXYMETHYL)-CYCLOBUTYL]GUANINE AGAINST DIFFERENT HERPES VIRUSES1
  834. Mycophenolate mofetil strongly potentiates the anti-herpesvirus activity of acyclovir
  835. Polyanion Inhibitors of HIV and Other Viruses. 7. Polyanionic Compounds and Polyzwitterionic Compounds Derived from Cyclodextrins as Inhibitors of HIV Transmission
  836. The Antiherpesvirus Activity of H2G [(R)-9-[4-Hydroxy-2-(Hydroxymethyl)Butyl]Guanine] Is Markedly Enhanced by the Novel Immunosuppressive Agent Mycophenolate Mofetil
  837. 7-Deazaxanthine, a novel prototype inhibitor of thymidine phosphorylase
  838. Broad-Spectrum Antiviral Activity and Mechanism of Antiviral Action of the Fluoroquinolone Derivative K-12
  839. Synthesis, Antiviral and Cytostatic Activities of Carbocyclic Nucleosides Incorporating a Modified Cyclopentane Ring. Part 2:1Adenosine and Uridine Analogues
  840. Inhibitory Effects of Novel Nucleoside and Nucleotide Analogues on Epstein—Barr Virus Replication
  841. Superior cytostatic activity of the ganciclovir elaidic acid ester due to the prolonged intracellular retention of ganciclovir anabolites in herpes simplex virus type 1 thymidine kinase gene-transfected tumor cells
  842. The Novel Immunosuppressive Agent Mycophenolate Mofetil Markedly Potentiates the Antiherpesvirus Activities of Acyclovir, Ganciclovir, and Penciclovir In Vitro and In Vivo
  843. Intracellular Metabolism of the N7-Substituted Acyclic Nucleoside Analog 2-Amino-7-(1,3-dihydroxy-2-propoxymethyl)purine, a Potent Inhibitor of Herpesvirus Replication
  844. Differential anti-hepatitis B virus activity in vitro of three potent of inosine monophosphate dehydrogenase inhibitors: mycophenolic acid (MPA), 5-ethynyl-1-β-d-ribofuranosyli-midazole-4-carboxamide (EICAR) and ribavirin
  845. Inhibitory effect of 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) on hepatitis B virus replication in vitro
  846. The influences of immunosuppressive agents on HBV replication in vitro
  847. In Vitro and In Vivo Inhibition of Murine Gamma Herpesvirus 68 Replication by Selected Antiviral Agents
  848. Antiviral drug susceptibility of human herpesvirus 8.
  849. Phosphorylation of aciclovir, ganciclovir, penciclovir and S2242 by the cytomegalovirus UL97 protein: a quantitative analysis using recombinant vaccinia viruses
  850. Antiviral activity of a novel compound P-4018 against different strains of herpes simplex virus in vitro and in vivo
  851. Differential antiviral activity of several IMP dehydrogenase inhibitors
  852. Mycophenolate Mofetil markedly enhances the antiviral activity of acyclovir, ganciclovir and penciclovir against herpes simplex virus (wild type and TK− strains) and human cytomegalovirus
  853. Synthesis and antiviral evaluation of benzyl-substituted thiopurine and tiazofurin derivatives
  854. HPMPC (cidofovir), PMEA (adefovir) and Related Acyclic Nucleoside Phosphonate Analogues: A Review of their Pharmacology and Clinical Potential in the Treatment of Viral Infections
  855. Nucleosides and Nucleotides. Part 154. New Neplanocin Analogues. VIII. Synthesis and Biological Activity of 6'-C-Ethyl, -Ethenyl, and -Ethynyl Derivatives of Neplanocin A.
  856. Mechanism of the Antiviral Activity of New Aurintricarboxylic Acid Analogues
  857. Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections
  858. Polyanion Inhibitors of Human Immunodeficiency Virus and Other Viruses. Part 2. Polymerized Anionic Surfactants Derived from Amino Acids and Dipeptides†
  859. Synthesis and Antiviral Activity Evaluation of Some New Aminoadamantane Derivatives. 2
  860. Differential antiviral activity of derivatized dextrans
  861. Human cytomegalovirus modulates the Ca2+ response to vasopressin and ATP in fibroblast cultures
  862. Anti-HIV and anti-HCMV Activities of New Aurintricarboxylic Acid Analogues
  863. Human Cytomegalovirus Stimulates Thymidylate Synthase in Human Embryonic Lung Cells: A Possible Target for Anti-HCMV Therapy?
  864. In vivo Antiretroviral Efficacy of Oral bis(POM)-PMEA, the bis(Pivaloyloxymethyl)prodrug of 9-(2-Phosphonylmethoxyethyl) adenine (PMEA)
  865. Absence of Infectious Retinitis after Injection of Human Cytomegalovirus into Rabbit Eyes
  866. In vivo antiherpesvirus activity of N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine
  867. The N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine is a potent and selective inhibitor of herpesvirus replication.
  868. Host Defense Mechanisms Against Murine Cytomegalovirus Infection Induced by Poly l:C in Severe Combined Immune Deficient (SCID) Mice
  869. Calcineurin as a possible new target for treatment of Parkinson's disease
  870. Antiviral activity of a sulphated polysaccharide from the red seaweed nothogenia fastigiata
  871. In vitro and in vivo inhibition of ortho- and paramyxovirus infections by a new class of sulfonic acid polymers interacting with virus-cell binding and/or fusion.
  872. Mechanism of action of acyclic nucleoside phosphonates against herpes virus replication
  873. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice
  874. In vitro Activity of a Novel Series of Polyoxosilicotungstates against Human Myxo-, Herpes- and Retroviruses
  875. Inhibitory activity of S-adenosylhomocysteine hydrolase inhibitors against human cytomegalovirus replication
  876. Protective activity of lipid A analogue GLA-60 against murine cytomegalovirus infection in mice
  877. Protective activity of the lipid A analogue GLA-60 against murine cytomegalovirus infection in immunodeficient mice
  878. Activity of the anti-HIV agent 9-(2-phosphonyl-methoxyethyl)-2,6-diaminopurine against cytomegalovirus in vitro and in vivo
  879. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice
  880. Efficacy of oral 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the treatment of retrovirus and cytomegalovirus infections in mice
  881. Strategies for the treatment and prevention of cytomegalovirus infections
  882. Therapy for herpesvirus infections
  883. Mechanism of anti-human immunodeficiency virus action of polyoxometalates, a class of broad-spectrum antiviral agents.
  884. Poly(Hydroxy)Carboxylates as Selective Inhibitors of Cytomegalovirus and Herpes Simplex Virus Replication
  885. Sulfated polymers inhibit the interaction of human cytomegalovirus with cell surface heparan sulfate
  886. The mannose-specific plant lectins from Cymbidium hybrid and Epipactis helleborine and the (N-acetylglucosamine)n-specific plant lectin from Urtica dioica are potent and selective inhibitors of human immunodeficiency virus and cytomegalovirus replicati...
  887. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice
  888. Sensitive, reproducible and convenient fluorometric assay for the in vitro evaluation of anticytomegalovirus agents
  889. Inhibitory Effects of Polycations on the Replication of Enveloped Viruses (HIV, HSV, CMV, RSV, Influenza A Virus and Togaviruses) in vitro
  890. Antiviral activity of anti-cytomegalovirus agents (HPMPC, HPMPA) assessed by a flow cytometric method and DNA hybridization technique
  891. Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro
  892. Alpha-(1-3)- and alpha-(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro.
  893. Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-Dihydroxy-2-propoxymethyl)guanine (DHPG)
  894. Sulphated Polymers are Potent and Selective Inhibitors of Various Enveloped Viruses, Including Herpes Simplex Virus, Cytomegalovirus, Vesicular Stomatitis Virus, Respiratory Syncytial Virus, and Toga-, Arena- and Retroviruses
  895. Detection of substances recognized by antisera directed against vertebrate somatotropin, prolactin and placental lactogen, within the brain of the insect Locusta migratoria: A comparison of immunocytochemical localization patterns
  896. Detection of immediate early, early and late antigens of human cytomegalovirus by flow cytometry
  897. Antiviral Drugs
  898. Antiviral Drugs
  899. Methods in Anti-HCMV Research
  900. Selective inhibitors of the replication of poxviruses
  901. Faculty of 1000 evaluation for Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease.
  902. Faculty of 1000 evaluation for Viral reorganization of the secretory pathway generates distinct organelles for RNA replication.
  903. Discovery of Multitarget Agents Active as Broad-Spectrum Antivirals and Correctors of Cystic Fibrosis Transmembrane Conductance Regulator for Associated Pulmonary Diseases